In the area of targeted therapies, Therapeutic targeting of several prevalent genetic changes observed in OS, including TP53 break-down translocations and RB1 deletions that disrupt the expression of crucial tumor-suppressor proteins, has posed significant challenges. The gene discussed is RB1; the disease is neoplasm.